Literature DB >> 3466686

Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.

T T Chang, S Gulati, T C Chou, M Colvin, B Clarkson.   

Abstract

The development of suitable methods for purging the malignant cells contaminating the bone marrow of patients with cancer may offer a better chance of success for autologous bone marrow transplantation. In this paper, we further describe our efforts at purging acute myelogenous leukemia cells. HL-60, a promyelocytic leukemia cell line, was used as a model. 4-Hydroperoxycyclophosphamide (4-HC), VP-16-213 (VP-16), and Adriamycin were used alone or in combination to develop the best method to purge HL-60 cells. The cytotoxicity of 29.2 micrograms/ml (100 microM) of 4-HC was 99.8 +/- 0.12% (SD) on HL-60 cells and 82.5% on colony forming units-granulocyte, macrophage. Ninety-nine % of HL-60 cells and 72.7% of colony forming units-granulocyte, macrophage were inhibited by VP-16 at a concentration of 25 micrograms/ml (42.5 microM). The cytotoxicity of 1.5 micrograms/ml (2.76 microM) of Adriamycin on HL-60 cells was 98.6 +/- 0.8% and inhibited colony forming units-granulocyte, macrophage by 50.8%. The cytotoxicity and interactions of any two drug combinations at different combination ratios and the different effect levels were quantitatively determined by median effect plot and the multiple drug effect equation (T-C. Chou and P. Talalay. Adv. Enzyme Regul. 22: 27-55, 1984). The combination of 4-HC and VP-16 at a 4-HC:VP-16 drug ratio of 1:0.342 was found to be the best for selective toxicity towards HL-60 cells and was superior to the 4-HC-Adriamycin or VP-16 Adriamycin combination for usefulness in purging bone marrow.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3466686

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.

Authors:  G Nocentini; A Barzi; P Franchetti
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  The effect of high energy shock waves (HESW) on human bone marrow.

Authors:  C Yang; W D Heston; S Gulati; W R Fair
Journal:  Urol Res       Date:  1988

5.  Interaction between cisplatin, 5-fluorouracil and vincristine on human hepatoma cell line (7721).

Authors:  Wei-Xue Tang; Ping-Yan Cheng; Yun-Peng Luo; Rui-Xue Wang
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

6.  Relationships between various uses of antineoplastic drug-interaction terms.

Authors:  G L Wampler; W H Carter; E D Campbell; P A Keefe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

Authors:  K S Smith; B A Folz; E G Adams; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562.

Authors:  R Hoffman; L Graham; E S Newlands
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.